- Home
- SRRK vs RNA Comparison
SRRK vs RNA Comparison
Compare SRRK & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- RNA
- Stock Information
- Founded
- SRRK 2012
- RNA 2012
- Country
- SRRK United States
- RNA United States
- Employees
- SRRK N/A
- RNA N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- SRRK Health Care
- RNA Health Care
- Exchange
- SRRK Nasdaq
- RNA Nasdaq
- Market Cap
- SRRK 3.3B
- RNA 3.7B
- IPO Year
- SRRK 2018
- RNA 2020
- Fundamental
- Price
- SRRK $32.15
- RNA $29.52
- Analyst Decision
- SRRK Strong Buy
- RNA Strong Buy
- Analyst Count
- SRRK 7
- RNA 12
- Target Price
- SRRK $40.43
- RNA $68.25
- AVG Volume (30 Days)
- SRRK 1.1M
- RNA 1.4M
- Earning Date
- SRRK 05-06-2025
- RNA 05-08-2025
- Dividend Yield
- SRRK N/A
- RNA N/A
- EPS Growth
- SRRK N/A
- RNA N/A
- EPS
- SRRK N/A
- RNA N/A
- Revenue
- SRRK N/A
- RNA $10,897,000.00
- Revenue This Year
- SRRK N/A
- RNA N/A
- Revenue Next Year
- SRRK $601.05
- RNA $230.08
- P/E Ratio
- SRRK N/A
- RNA N/A
- Revenue Growth
- SRRK N/A
- RNA 13.98
- 52 Week Low
- SRRK $6.76
- RNA $21.56
- 52 Week High
- SRRK $46.98
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- SRRK 36.26
- RNA 43.70
- Support Level
- SRRK $31.60
- RNA $30.12
- Resistance Level
- SRRK $33.96
- RNA $33.13
- Average True Range (ATR)
- SRRK 1.62
- RNA 2.14
- MACD
- SRRK -0.02
- RNA -0.05
- Stochastic Oscillator
- SRRK 20.86
- RNA 11.94
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.